EXPERT PERSPECTIVE VIRTUAL TUMOR BOARD
Arlene O. Siefker-Radtke, MD:I’d like to move on to case number 2, which is a 68-year-old Caucasian man who was referred to urology after an evaluation for gross hematuria. As anticipated in most bladder cancer patients, he has a past history of hypertension and COPD [chronic obstructive pulmonary disease] from smoking with a 30-year smoking history. He has a cystoscopy from one of D. Brown’s colleagues showing a nodular 8 cm mass at the left urethral orifice. And on transurethral resection, has a high-grade urothelial carcinoma invading into the muscularis propria. His PD-L1 [programmed death-ligand 1] score by CPS [combined positive score] was greater than 10.
However, on imaging, we had some unfortunate news where he had both enlarged pelvic lymph nodes and lung metastases. A bone scan was negative, but his creatinine clearance calculated by Cockcroft-Gault was about 42 mL/minute. So he’s now been diagnosed with a metastatic bladder cancer with borderline or poor kidney function.
Transcript edited for clarity.
NIAGARA Trial Results Show Durvalumab/Chemo Improves EFS, OS in Cisplatin-Eligible MIBC
September 15th 2024In the NIAGARA trial, significant event-free survival and overall survival gains were observed with neoadjuvant durvalumab plus chemotherapy, followed by adjuvant durvalumab in cisplatin-eligible bladder cancer.
Read More
Extended Follow-Up Bolsters Adjuvant Pembrolizumab DFS Rate in MIUC
September 15th 2024Longer follow-up from the phase 3 AMBASSADOR trial showed adjuvant pembrolizumab to demonstrate a statistically significant and clinically meaningful improvement in disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma.
Read More